QUANTITY LIMIT PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)

ELMIRON (pentosan polysulfate sodium)

Status: CVS Caremark® Criteria

Type: Quantity Limit; Post Limit Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Elmiron (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

INITIAL QUANTITY LIMIT**

INITIAL LIMIT QUANTITY

Drug 1 Month Limit* 3 Month Limit*

Elmiron (pentosan polysulfate sodium) 90 capsules / 25 days 270 capsules / 75 days

*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

COVERAGE CRITERIA

Bladder Pain or Discomfort Associated with Interstitial Cystitis

Authorization may be granted when the requested drug is being prescribed for the relief of bladder pain or discomfort associated with interstitial cystitis.

QUANTITY LIMITS APPLY

120 capsules per 25 days* or 360 capsules per 75 days*

*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

DURATION OF APPROVAL (DOA)

• 2961-HJ: DOA: 6 months

REFERENCES

- Elmiron [package insert]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; March 2021.
- Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed March 18, 2024.
- 3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 03/18/2024).

Elmiron Limit, Post PA Policy UDR 05-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428J 021423

^{**}If the patient is requesting more than the initial quantity limit, the claim will reject with a message indicating that a prior authorization is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

